首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis.
【24h】

Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis.

机译:烟曲霉在体外预先暴露于伏立康唑或泊沙康唑是否会分别影响其毒力以及随后的泊沙康唑或伏立康唑的体内活性?飞曲霉病模型的研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: Voriconazole and posaconazole are effective as both prophylaxis and treatment for invasive aspergillosis (IA) in immunocompromised patients. Hence, it is important to determine whether Aspergillus pre-exposure to voriconazole or posaconazole diminishes subsequent posaconazole or voriconazole activity, respectively. METHODS: We used Aspergillus fumigatus (AF) 293 conidia with or without prior exposure to voriconazole or posaconazole [three serial passages on plates containing regular yeast extract-glucose (YAG) media, YAG+0.0625 mg/L voriconazole or YAG+0.025 mg/L posaconazole]. Toll-deficient Drosophila melanogaster flies were infected by injection, and 8 day survival was monitored. Following infection, flies were fed either regular food, food containing 1000 mg/L voriconazole (posaconazole-exposed conidia) or 1000 mg/L posaconazole (voriconazole-exposed conidia). Voriconazole and posaconazole concentrations in flies were confirmed by HPLC. RESULTS: AF inoculation resulted in 71% mortality 8 days post-infection (median survival 4 days). Prior conidial exposure to voriconazole or posaconazole did not affect mortality (73%, P = 0.8 for voriconazole pre-exposed and 76%, P = 0.49 for posaconazole pre-exposed). Voriconazole treatment post-infection had a protective effect, reducing mortality to 42% (P = 0.0002), while prior conidial exposure to posaconazole did not alter the protective effect of voriconazole (34% 8 day mortality, P = 0.35). Likewise, posaconazole treatment post-infection reduced mortality to 36%, while prior conidial exposure to voriconazole did not alter the protective effect of posaconazole (39% mortality, P = 0.92). Median fly homogenate concentrations of voriconazole and posaconazole were 0.44 and 2.05 mg/L, respectively. CONCLUSIONS: Prior exposure of AF to voriconazole or posaconazole did not affect the virulence of AF nor the subsequent activity of the alternate triazole in a Drosophila model of IA.
机译:目的:伏立康唑和泊沙康唑可有效预防和治疗免疫功能低下的侵袭性曲霉病(IA)。因此,重要的是确定曲霉菌预先暴露于伏立康唑或泊沙康唑是否会分别降低随后的泊沙康唑或伏立康唑的活性。方法:我们使用烟曲霉(Aspergillus fumigatus,AF)293分生孢子,有或没有事先暴露于伏立康唑或泊沙康唑[在含有常规酵母提取物葡萄糖(YAG)培养基,YAG + 0.0625 mg / L伏立康唑或YAG + 0.025 mg / L泊沙康唑]。通过注射感染收费不足的果蝇黑蝇,并监测8天生存期。感染后,为苍蝇喂食常规食物,含有1000 mg / L伏立康唑(暴露于波塞康唑的分生孢子)或1000 mg / L泊沙康唑(暴露于伏立康唑的分生孢子)的食物。通过HPLC确认果蝇中伏立康唑和泊沙康唑的浓度。结果:AF接种导致感染后8天的死亡率为71%(中位生存期为4天)。预先分生孢子体对伏立康唑或泊沙康唑的接触不会影响死亡率(73%,伏立康唑预暴露的P = 0.8,泊沙康唑预暴露的76%,P = 0.49)。伏立康唑治疗在感染后具有保护作用,将死亡率降低至42%(P = 0.0002),而先前分生孢子暴露于泊沙康唑并没有改变伏立康唑的保护作用(34%的8天死亡率,P = 0.35)。同样,泊沙康唑治疗在感染后将死亡率降低到36%,而先前分生孢子暴露于伏立康唑也不会改变泊沙康唑的保护作用(死亡率39%,P = 0.92)。伏立康唑和泊沙康唑的苍蝇匀浆浓度中位数分别为0.44和2.05 mg / L。结论:在果蝇IA模型中,事先将AF暴露于伏立康唑或泊沙康唑不会影响AF的毒性,也不会影响替代三唑的后续活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号